Kidney health may change how body handles experimental drug ESK-001

NCT ID NCT06962774

Completed Knowledge-focused Sponsor: Alumis Inc Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed phase 1 study looked at how different levels of kidney function affect the way the body processes a single dose of ESK-001, an experimental drug. Sixteen participants with healthy kidneys or mild, moderate, or severe kidney impairment each took one oral dose. Researchers measured drug levels in the blood and monitored for side effects to understand how the kidneys impact the drug's breakdown and removal.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ESK-001
What this could lead to: If successful, this study will help determine the right dose of ESK-001 for people with kidney problems, making future treatments safer and more effective.
What could go wrong: This is a very early, small study (16 people) focused on drug levels, not on treating any disease. It only looks at a single dose, so long-term effects or benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RENAL IMPAIRMENT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

impaired renal function disease kidney failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL IMPAIRMENT

Contacts and locations

Locations

Advanced Pharma CR

Miami, Florida, 33147, United States
Floridian Clinical Research

Miami Lakes, Florida, 33016, United States
Orlando Clinical Research Center

Orlando, Florida, 32809, United States
Panax Clinical Research

Miami Lakes, Florida, 33014, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.